Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
ContextVision AB (publ) is a Swedish medical technology software company founded in 1983, specializing in image analysis and artificial intelligence solutions for healthcare imaging. It develops proprietary software that enhances image quality in medical systems, including 2D/3D/4D ultrasound, X-ray, radiography, mammography, and MRI, enabling faster and more reliable diagnostics across fields like radiology, cardiology, women's health, and point-of-care applications. Notable platforms include Rivent for ultrasound image enhancement and Altumira for scatter correction in radiography, which supports radiation dose reduction while improving clarity. As a global market leader, ContextVision partners with leading original equipment manufacturers (OEMs), with its solutions installed in over 400,000 systems worldwide. The company maintains a strong focus on research and development, employing around 44 people, half dedicated to innovation, and operates across Asia, Europe, and America with local presence in key markets like the U.S., Japan, China, and South Korea. Recent strategic collaborations, such as with the University of Washington and University of Waterloo, advance AI-driven diagnostics for liver diseases like MASLD, underscoring its role in transforming medical imaging standards.
NOK 3.40
+NOK 0.32 (+10.39%)
Price from 9 days ago
The business is unprofitable at the operating level (-2.66% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 20.2% YoY. Margins deteriorated 18.9pp alongside, both lines moving the wrong way.
At 55x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Free cash flow declined 99% versus the prior year, cash generation momentum has weakened.
55.5x earnings, 47.4x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 113M
▼ -20.2% YoY
Net Income (TTM)
kr 5M
▼ -97.2% YoY
Op. Margin
2.64%
▼ -18.9pp YoY
ROIC
-2.73%
▼ -21.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 5M
▼ -99.3% YoY
Op. Cash Flow (TTM)
kr 10M
▼ -97.1% YoY
Net Debt
-kr 57M
Net Cash Position
Cash & Equiv.
kr 70M
3Y CAGR: -2.2%
3Y CAGR: -78.8%
Continue Research
At a P/E of 55.5 and a price-to-free-cash-flow of 47.4, ContextVision AB (publ) (CONTX.XOSL) trades above a two-stage DCF intrinsic value of about SEK 1.98 per share, so at SEK 3.40 the stock looks overvalued (41.8% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, ContextVision AB (publ) scores 28/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 1.98 per share for CONTX.XOSL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 1.48. At today's SEK 3.40, that puts the stock about 41.8% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
ContextVision AB (publ) scores 28 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 2.6% operating margin and a -2.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CONTX.XOSL currently trades above its estimated intrinsic value and scores 28/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.